Sanofi appoints two executive members
pharmafile | May 3, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi, executive
Sanofi has announced a new commercial organisation which results in the appointment of two executives.
Following the retirement of Hanspeter Spek, president, Global Operations – two new units will be created: Global Commercial Operations and Global Divisions and Strategic Commercial Development, to replace the former unit.
Peter Guenter (pictured), currently senior vice president, Europe, will be appointed executive vice president, Global Commercial Operations.
Pascale Witz, currently president and chief executive of Medical Diagnostics at GE Healthcare, will join Sanofi and be appointed executive vice president, Global Divisions & Strategic Commercial Development.
Christopher Viehbacher, Sanofi’s chief executive said: “The appointment of these two new leaders will enable us to strengthen our growth platforms and ensure the success of our new products to deliver a sustainable future for our company. Peter is a proven leader with a strong track record in achieving ambitious commercial objectives.
“His most recent experience in Europe has prepared him well for driving growth in the rapidly evolving healthcare environment. Pascale’s diversified experience in healthcare and acute commercial focus will be a great addition to Sanofi. I am confident that her expertise in diagnostics and medical technology will reinforce our mission as an integrated global healthcare company.”
As executive vice president, Global Commercial Operations, Guenter will focus on in-market execution across the diverse regions of North America, Latin America, Europe, Asia, Japan and Pacific and Intercontinental.
Witz will be responsible for setting the strategic direction and guiding product development of the Group key businesses. She will have direct responsibilities for the Diabetes, Oncology & PCS (Pharmaceutical Customer Solution) divisions, as well as a new structure for consumer healthcare.
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
